Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Personalized Medicine in Cancer Therapy: Mechanism, Approaches and Techniques
share announcement

Personalized Medicine in Cancer Therapy: Mechanism, Approaches and Techniques

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 8747

Special Issue Editors

Dr. Michele Zanoni

E-Mail Website
Guest Editor
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"-IRST S.r.l., 47014 Meldola, Italy
Interests: 3D models; senescence; cancer; therapy resistance; metabolism; extracellular matrix (ECM)
Special Issues, Collections and Topics in MDPI journals
Dr. Michela Cortesi

E-Mail Website
Guest Editor
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l., 47014 Meldola, Italy
Interests: pharmacology; 3D models; senescence; tumor microenvironment (TME); unfolded protein response (UPR)

Special Issue Information

Dear Colleagues, 

Personalized medicine differs from standard treatment approaches due to the identification of factors (e.g., molecular features, phenotypes, environment, biomarkers) making individual patients eligible for a specific treatment. The tumor microenvironment (TME) is attracting growing attention in cancer research. This highly complex network composed of non-tumor cells, extracellular matrix (ECM) proteins, and secreted factors modulates and is modulated by malignant cells. The dynamic landscape of the TME impacts on treatment outcome, leading to therapy resistance, and contributes to tumor heterogeneity, which represents a critical factor driving tumor progression and dissemination. This Special Issue will host review, opinion, short communication, and research articles focusing on personalized medicine-exploring strategies to model and target the TME. We particularly welcome articles integrating preclinical models (e.g., 3D models, organoids), omics (e.g., metabolomics, proteomics, genomics), and bioinformatics analyses. Special attention will be given to cross-disciplinary approaches involving clinicians, biologists, chemists, physicists, engineers, etc.

Dr. Michele Zanoni
Dr. Michela Cortesi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tumor microenvironment
  • personalized medicine
  • cancer
  • therapy resistance
  • metabolomics
  • proteomics
  • genomics
  • organoids

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

20 pages, 6852 KiB  
Article
IL4Rα and IL13Rα1 Are Involved in the Development of Human Gallbladder Cancer
by Sung Woo Ahn, Chang Min Lee, Mi-Ae Kang, Usama Khamis Hussein, Ho Sung Park, Ae-Ri Ahn, Hee Chul Yu, Jae Do Yang, Yung-Hun Yang, Kyungmoon Park, Jongsung Lee, Kyu Yun Jang and See-Hyoung Park
J. Pers. Med. 2022, 12(2), 249; https://doi.org/10.3390/jpm12020249 - 9 Feb 2022
Cited by 3 | Viewed by 2059
Abstract
Background: Gallbladder cancer is commonly associated with inflammation, which indicates that inflammation-related cytokines and cytokine receptors are related to the progression of gallbladder cancers. Interleukin 4 (IL4) is a well-known cytokine that promotes the differentiation of naive helper T cells (Th0) to T [...] Read more.
Background: Gallbladder cancer is commonly associated with inflammation, which indicates that inflammation-related cytokines and cytokine receptors are related to the progression of gallbladder cancers. Interleukin 4 (IL4) is a well-known cytokine that promotes the differentiation of naive helper T cells (Th0) to T helper type 2 cells (Th2). IL13 is a cytokine that is secreted by Th2 cells. IL4 and IL13 are closely related in immune responses. However, the role of IL4Rα and IL13Rα1 signaling pathway has not been fully understood in the development of gallbladder cancer. Methods: In human gallbladder carcinomas, the expression of IL4Rα and IL13Rα1 were evaluated with immunohistochemical staining in tissue microarray tissue sections. After knockdown of IL4Rα or IL13Rα1, cell assays to measure the proliferation and apoptosis and Western blotting analysis were conducted in SNU308 human gallbladder cancer cells. Since Janus kinases2 (JAK2) was considered as one of the down-stream kinases under IL4Rα and IL13Rα1 complex, the same kinds of experiments were performed in SNU308 cells treated with AZD1480, Janus-associated kinases2 (JAK2) inhibitor, to demonstrate the cytotoxic effect of AZD1480 in SNU308 cells. Results: Immunohistochemical expression of IL4Rα was significantly associated with the expression of IL13Rα1 in human carcinoma tissue. In univariate analysis, nuclear expression of IL4Rα, cytoplasmic expression of IL4Rα, nuclear expression of IL13Rα1, and cytoplasmic expression of IL13Rα1 were significantly associated with shorter overall survival and shorter relapse-free survival. Multivariate analysis revealed nuclear expression of IL4Rα as an independent poor prognostic indicator of overall survival and relapse-free survival. Then, we found that knockdown of IL4Rα or IL13Rα1 decreased viability and induced apoptosis in SNU308 cells via activation of FOXO3 and similarly, AZD1480 decreased viability and induced apoptosis in SNU308 cells with dose dependent manner. Conclusions: Taken together, our results suggest that IL4Rα and IL13Rα1 might be involved in the development of human gallbladder cancer cells and IL4Rα and IL13Rα1 complex/JAK2 signaling pathway could be efficient therapeutic targets for gallbladder cancer treatment. Full article
(This article belongs to the Special Issue Personalized Medicine in Cancer Therapy: Mechanism, Approaches and Techniques)
►▼ Show Figures

Figure 1

8 pages, 375 KiB  
Communication
Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
by Sara Bravaccini and Roberta Maltoni
J. Pers. Med. 2021, 11(11), 1211; https://doi.org/10.3390/jpm11111211 - 16 Nov 2021
Cited by 11 | Viewed by 2716
Abstract
Trop-2 is an ideal candidate for targeted therapeutics because it is a transmembrane protein with an extracellular domain overexpressed in a wide variety of tumors, and is upregulated in normal cells. Consequently, several Trop-2-targeted drugs have recently been developed for clinical use, such [...] Read more.
Trop-2 is an ideal candidate for targeted therapeutics because it is a transmembrane protein with an extracellular domain overexpressed in a wide variety of tumors, and is upregulated in normal cells. Consequently, several Trop-2-targeted drugs have recently been developed for clinical use, such as anti-Trop-2 antibodies. Sacituzumab govitecan, a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate, was recently approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. In Italy, this treatment cannot be used in clinical practice because it has not yet been approved by the Agenzia Italiana del Farmaco (AIFA, Rome, Italy). In Italy, this is not a new problem, in fact, when a new compound is approved by the U.S. and Europe, there is often a delay in its approval for use. The adoption of universal guidelines and the standardization of Trop-2 evaluation is urgently needed. Full article
(This article belongs to the Special Issue Personalized Medicine in Cancer Therapy: Mechanism, Approaches and Techniques)
►▼ Show Figures

Figure 1

Review

Jump to: Research

22 pages, 3223 KiB  
Review
Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches
by Giacomo Miserocchi, Chiara Spadazzi, Sebastiano Calpona, Francesco De Rosa, Alice Usai, Alessandro De Vita, Chiara Liverani, Claudia Cocchi, Silvia Vanni, Chiara Calabrese, Massimo Bassi, Giovanni De Luca, Giuseppe Meccariello, Toni Ibrahim, Marco Schiavone and Laura Mercatali
J. Pers. Med. 2022, 12(6), 854; https://doi.org/10.3390/jpm12060854 - 24 May 2022
Cited by 14 | Viewed by 3253
Abstract
Head and neck cancers (HNCs) represent the sixth most widespread malignancy worldwide. Surgery, radiotherapy, chemotherapeutic and immunotherapeutic drugs represent the main clinical approaches for HNC patients. Moreover, HNCs are characterised by an elevated mutational load; however, specific genetic mutations or biomarkers have not [...] Read more.
Head and neck cancers (HNCs) represent the sixth most widespread malignancy worldwide. Surgery, radiotherapy, chemotherapeutic and immunotherapeutic drugs represent the main clinical approaches for HNC patients. Moreover, HNCs are characterised by an elevated mutational load; however, specific genetic mutations or biomarkers have not yet been found. In this scenario, personalised medicine is showing its efficacy. To study the reliability and the effects of personalised treatments, preclinical research can take advantage of next-generation sequencing and innovative technologies that have been developed to obtain genomic and multi-omic profiles to drive personalised treatments. The crosstalk between malignant and healthy components, as well as interactions with extracellular matrices, are important features which are responsible for treatment failure. Preclinical research has constantly implemented in vitro and in vivo models to mimic the natural tumour microenvironment. Among them, 3D systems have been developed to reproduce the tumour mass architecture, such as biomimetic scaffolds and organoids. In addition, in vivo models have been changed over the last decades to overcome problems such as animal management complexity and time-consuming experiments. In this review, we will explore the new approaches aimed to improve preclinical tools to study and apply precision medicine as a therapeutic option for patients affected by HNCs. Full article
(This article belongs to the Special Issue Personalized Medicine in Cancer Therapy: Mechanism, Approaches and Techniques)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop